Thursday, April 24

New Delhi: The Ministry of Health & Family Welfare (Mohfw) has named Dr. Soumya Swaminathan, former chief scientist of the World Health Organization, as principal advisor for its National Tuberculosis Elimination Programme. Swaminathan, who played a key role during the pandemic outbreak, will provide technical advice on the overall strategy to achieve programme goals, suggest policy directions and necessary course corrections for optimal outcomes, and advise on research strategy. Her appointment is on a pro bono basis. The Mohfw said “She will also assist in the formation of expert groups with top talent globally. Additionally, she will support the union health ministry, state officials, and development partners in assessing the impact of the programme.” Swaminathan has also served as director general of the Indian Council of Medical Research (ICMR) during 2015-2017.

At WHO, Swaminathan led the science division with a focus on research, quality assurance of norms and standards and digital health. She played a key role during the pandemic in coordinating scientific efforts at the WHO, as well as in setting up Covax, with a focus on equitable vaccine distribution to LMICs. Swaminathan is a paediatrician and a globally recognized researcher on tuberculosis and HIV. She has a vast experience of over 30 years in clinical care and research, and has worked throughout her career to translate research into impactful programmes.

Share.
Leave A Reply

Doctors Post is a news portal tailored to provide current news & updates on issues related exclusively to medical & healthcare professionals. The content of Doctor Post is judiciously authored by a dedicated team of legal experts, doctors and reporters.  The intent of the content is to expeditiously update doctor’s information & news necessary for the smooth functioning of their profession.

© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution

Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.

Exit mobile version